{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:32Z","timestamp":1753868672201,"version":"3.41.2"},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Follicular lymphoma (FL) is the most common indolent non\u2010Hodgkin lymphoma (NHL) in the United States and Europe. However, data on FL from Latin America are scant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aims at better understand the clinical features, treatment patterns and outcomes of patients with FL in Chile. Of special interest was to evaluate POD24 as an adverse marker.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>We collected retrospective data from 722 patients 15\u2009years or older diagnosed with FL and treated in 17 cancer centers in Chile between 2000 and 2019. Time to first treatment (TTFT), progression\u2010free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method. Cox proportional\u2010hazard regression models were fitted to investigate prognostic factor. The median age at diagnosis was 62 with a female predominance (63%); 73% of patients had advance stage disease and 68% had bone marrow involvement; 63% had intermediate or high FLIPI scores. The 1\u2010year TTFT rate was 96%, and 30% of patients received chemoimmunotherapy. Adding rituximab to chemotherapy was associated with a higher complete response (69% vs. 60%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and superior median OS (16 vs. 8\u2009years; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Patients who experience POD24 had an inferior median OS (2.4 vs. 15\u2009years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study shows a female predominance in patients with FL in Chile and confirms superior response and survival outcomes with adding rituximab to chemotherapy. Our study also confirms a poor OS in patients who experience POD24.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.2126","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T03:40:54Z","timestamp":1727062854000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-3871","authenticated-orcid":false,"given":"Mar\u00eda\u00a0Elena","family":"Cabrera","sequence":"first","affiliation":[{"name":"Hospital del Salvador Universidad de Chile  Santiago Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Hospital del Salvador  Providencia Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeska","family":"Vega","sequence":"additional","affiliation":[{"name":"Hospital San Juan de Dios  Santiago Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hern\u00e1n","family":"Rojas","sequence":"additional","affiliation":[{"name":"Hospital S\u00f3tero del R\u00edo  Santiago Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Pizarro","sequence":"additional","affiliation":[{"name":"Hospital San Borja Arriar\u00e1n  Santiago Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rojas","sequence":"additional","affiliation":[{"name":"Hospital Gustavo Fricke  Valpara\u00edso Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Calderon","sequence":"additional","affiliation":[{"name":"Hospital Regional de Valdivia  Valdivia Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Oliva","sequence":"additional","affiliation":[{"name":"Hospital Las Higueras de Talcahuano  Talcahuano Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Hales","sequence":"additional","affiliation":[{"name":"Hospital Juan No\u00e9  Arica Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardita","family":"Rojas","sequence":"additional","affiliation":[{"name":"Hospital Carlos van Buren  Valpara\u00edso Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvila","family":"Intriago","sequence":"additional","affiliation":[{"name":"Hospital Regional de La Serena  La Serena Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Capurro","sequence":"additional","affiliation":[{"name":"Hospital Dr. Hernan Henriquez Aravena  Temuco Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.\u00a0Luisa","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Hospital Regional de Osorno  Osorno Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge\u00a0J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancies Dana\u2010Farber Cancer Institute, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.654471"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201003\u2010491514"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26737"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.251"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01048-6"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30155-8"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.8290"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007949"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082412"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5083"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34221"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-013367"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds429"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04025-2"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263"},{"issue":"3","key":"e_1_2_9_29_1","article-title":"Survival by First\u2010Line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population\u2010Based Study in Sweden","volume":"7","author":"Weibull C. E.","year":"2023","journal-title":"Hema"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00400"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01535-y"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0299-0"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12120"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7577"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2547"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.19.00025"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.02.001"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94"},{"issue":"9","key":"e_1_2_9_39_1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4067\/S0034-98872007000900003","article-title":"Mieloma m\u00faltiple en Chile: Caracter\u00edsticas cl\u00ednicas y Sobrevida [Clinical Features and Survival of Chilean Patients With Multiple Mieloma]","volume":"135","author":"Conte L. G.","year":"2007","journal-title":"Revista M\u00e9dica de Chile"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.4067\/s0034-98872018000700869"},{"key":"e_1_2_9_41_1","unstructured":"CRUK Myeloma Statistics2019 https:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/myeloma."},{"issue":"1","key":"e_1_2_9_42_1","first-page":"3","article-title":"Epidemiology, Staging, and Management of Multiple Myeloma","volume":"9","author":"Padala S. A.","year":"2021","journal-title":"Medical Science"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-440073"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2141960"},{"key":"e_1_2_9_45_1","unstructured":"Human Development Report 2021\u201322: Uncertain Times Unsettled Lives: Shaping our Future in a Transforming World (8 September 2022) 272\u2013276. ISBN 978\u20109\u2010211\u201026451\u20107. Archived (PDF) from the original on 8 September 2022. Retrieved 8 September 2022.https:\/\/www.un.org\/development\/desa\/en\/."}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.2126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T08:22:01Z","timestamp":1727425321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.2126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/cnr2.2126"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.2126","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2023-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2126"}}